Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.34 |
| ▸ | OTUB1 | Q96FW1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956546 | 0.91 | ESR1 (0.43) | ESR1TP53MAPTLMNAMEN1 | |
| Hydrochloric Acid SCHEMBL9956229 | 0.90 | ESR1 (0.42) | ESR1TP53MAPTLMNAMEN1 | |
| SCHEMBL9956414 | 0.87 | ESR1 (0.46) | ESR1TP53MAPTS1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL9955635 | 0.86 | ESR1 (0.45) | ESR1TP53MAPTS1PR1S1PR3 | |
| SCHEMBL10169697 | 0.85 | TP53 (0.45) | TP53MAPTLMNAMEN1KMT2A | |
| SCHEMBL17899946 | 0.85 | ESR1 (0.42) | ESR1 | |
| SCHEMBL10169694 | 0.85 | TP53 (0.43) | TP53MAPTLMNAMEN1KMT2A | |
| SCHEMBL9957139 | 0.85 | ESR1 (0.43) | ESR1TP53MAPTLMNAMEN1 | |
| SCHEMBL10169705 | 0.84 | ESR1 (0.43) | ESR1S1PR1S1PR3USP2USP1 | |
| SCHEMBL10169702 | 0.83 | TP53 (0.41) | ESR1TP53MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| EP-2655367-B1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| EP-2655367-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | Merck Sharp & Dohme B.V. (NL) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | ESR2, ESR1, GPER1 | ESR1 2/4885TP53 284/4885MAPT 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.